AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23052033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23052033 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-077825 (500 mg)
Number of subjects: 0
Study 23052033 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-077825 (1000 mg)
Number of subjects: 0
Study 22073219 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (25-50 mg once daily for 8 weeks)
Number of subjects: 40
Study 18926569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible artemether-lumefantrine tablets
Number of subjects: 899
Study 18926569 — intervention group
Group type: COMPARATOR
Intervention: Crushed artemether-lumefantrine tablets
Number of subjects: 899
Study 16446752 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (RSG) 8 mg
Number of subjects: 511
Study 16446752 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (RSG) 2 mg
Number of subjects: 511
Study 16446752 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (RSG) 4 mg
Number of subjects: 511
Study 16446752 — intervention group
Group type: COMPARATOR
Intervention: rosiglitazone (RSG) 2, 4, or 8 mg
Number of subjects: 511
Study 12587890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion (0.3 g x kg body mass(-1))
Number of subjects: 7
Study 12587890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 10694768 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index (GI) spaghetti meal
Number of subjects: 10
Study 10694768 — intervention group
Group type: COMPARATOR
Intervention: High‐GI white wheat bread (WWB) reference meal
Number of subjects: 10
Study 9096584 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin plus mezlocillin
Number of subjects: 128
Study 9096584 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 128
Study 8213103 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/NET formulation (EE 35 micrograms and norethisterone 0.5 mg on days 1‐7 and days 17‐21, elevated to 1.0 mg during days 8‐16)
Number of subjects: 196
Study 8213103 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/LGN formulation (EE 30 micrograms on days 1‐6 and days 12‐21, 40 micrograms on days 7‐11, phased levonorgestrel: 50 micrograms (days 1‐6), 75 micrograms (days 7‐11), and 125 micrograms (days 12‐21)
Number of subjects: 196
Study 3777330 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (single dose)
Number of subjects: 176
Study 3777330 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 176
Study 30572916 — intervention group
Group type: EXPERIMENTAL
Intervention: One cycle of GnRH agonist
Number of subjects: 421
Study 30572916 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycles of GnRH agonist
Number of subjects: 421
Study 27793181 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (ICBT) programme FearFighter™, nine sessions with weekly telephone contact
Number of subjects: 64
Study 27793181 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (ICBT) programme FearFighter™
Number of subjects: 64
Study 27793181 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 64
Study 24628464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 30
Study 24628464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22031515 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroid ablation (thyroidectomy plus (131)I)
Number of subjects: 52
Study 22031515 — intervention group
Group type: COMPARATOR
Intervention: Thyroidectomy (TX)
Number of subjects: 52
Study 20696074 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler imaging (LDI)
Number of subjects: 44
Study 20696074 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingertip lacticemy (FTL)
Number of subjects: 44
Study 20696074 — intervention group
Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy (NFC)
Number of subjects: 44
Study 20696074 — intervention group
Group type: COMPARATOR
Intervention: Cold stimulus (CS)
Number of subjects: 44
Study 17869296 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 25
Study 17869296 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil in patients with ASIA classification A and spinal cord injury above T6
Number of subjects: 25
Study 17869296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 15090124 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer-reported implementation ratings
Number of subjects: 0
Study 15090124 — intervention group
Group type: COMPARATOR
Intervention: Provider self-reported implementation ratings
Number of subjects: 0
Study 11308105 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers' arms
Number of subjects: 20
Study 11308105 — intervention group
Group type: COMPARATOR
Intervention: Incubator
Number of subjects: 20
Study 9041301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group viewed and received a copy of a videotape titled 'Feeding Your Baby With Love'
Number of subjects: 59
Study 9041301 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly described in the abstract)
Number of subjects: 59
Study 8177844 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation programme for 3 weeks including passive mobilization, respiratory exercises, and endurance exercise on an ergometric cycle.
Number of subjects: 48
Study 8177844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in physical activity level).
Number of subjects: 48
Study 8177844 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation programme for 3 weeks.
Number of subjects: 48
Study 3109142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (20 mg orally t.i.d. for 3 patients, 20 mg b.i.d. for 5 patients)
Number of subjects: 17
Study 3109142 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg orally t.i.d.)
Number of subjects: 17
Study 30696556 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization
Number of subjects: 91
Study 30696556 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging–guided focused ultrasound surgery
Number of subjects: 91
Study 29636355 — intervention group
Group type: EXPERIMENTAL
Intervention: Family consultation (n=60)
Number of subjects: 120
Study 29636355 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control (n=60)
Number of subjects: 120
Study 28768069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO₂) at 1.5 ATA for 60 minutes daily for 40 sessions
Number of subjects: 71
Study 28768069 — intervention group
Group type: COMPARATOR
Intervention: Sham chamber sessions at 1.2 ATA, air for 60 minutes daily for 40 sessions
Number of subjects: 71
Study 25179788 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor (MZ) given as a single dose to 30 poor mobilizers (PM)
Number of subjects: 90
Study 25179788 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF + Plerixafor (MZ)
Number of subjects: 90
Study 25179788 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF alone
Number of subjects: 90
Study 22455385 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% oxytetracycline hydrochloride three times a day for 1 week
Number of subjects: 90
Study 22455385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 22455385 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 90
Study 19174829 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Milk (WM)
Number of subjects: 83
Study 19174829 — intervention group
Group type: COMPARATOR
Intervention: Infant Formula
Number of subjects: 83
Study 19174829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil
Number of subjects: 83
Study 19174829 — intervention group
Group type: COMPARATOR
Intervention: No Fish Oil
Number of subjects: 83
Study 17461394 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate
Number of subjects: 85
Study 17461394 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone diproprionate and betamethasone sodium phosphate
Number of subjects: 85
Study 15918927 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported vegetable and fruit intake categorized into groups: </=1 serving, 2-3 servings, and >/=4 servings per day
Number of subjects: 1598
Study 15918927 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported vegetable intake
Number of subjects: 1598
Study 11817491 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 102
Study 11817491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 10634964 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 200 mg daily
Number of subjects: 32
Study 10634964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7717315 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (325 mg)
Number of subjects: 47
Study 7717315 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain aspirin (325 mg)
Number of subjects: 47
Study 7717315 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 47
Study 2037955 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole treatment (250 mg tid for 7 days) plus debridement
Number of subjects: 39
Study 2037955 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment plus debridement (positive control)
Number of subjects: 39
Study 2037955 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole treatment
Number of subjects: 39
Study 2037955 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (positive control)
Number of subjects: 39
Study 6786566 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded analgesic tablets
Number of subjects: 0
Study 6786566 — intervention group
Group type: COMPARATOR
Intervention: Unbranded analgesic tablets
Number of subjects: 0
Study 6786566 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert formulation)
Number of subjects: 0
Study 6786566 — intervention group
Group type: EXPERIMENTAL
Intervention: Active formulation (branded)
Number of subjects: 0
Study 31426749 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/10 mg
Number of subjects: 50
Study 31426749 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 10 mg
Number of subjects: 50
Study 28337563 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) combined with facial exercise treatment
Number of subjects: 46
Study 28337563 — intervention group
Group type: COMPARATOR
Intervention: Facial exercise treatment alone
Number of subjects: 46
Study 26402762 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 26402762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24088280 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC), distance <30 miles
Number of subjects: 503
Study 24088280 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC), distance ≥30 miles
Number of subjects: 503
Study 24088280 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine, distance <30 miles
Number of subjects: 503
Study 24088280 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine, distance ≥30 miles
Number of subjects: 503
Study 21867390 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg/0.2 ml subcutaneous (sc) 2 hr before surgery
Number of subjects: 50
Study 21867390 — intervention group
Group type: COMPARATOR
Intervention: Control group (no enoxaparin)
Number of subjects: 50
Study 19626385 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CCTA)
Number of subjects: 199
Study 19626385 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA) planned based on CCTA results
Number of subjects: 199
Study 17760592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional steroids
Number of subjects: 10
Study 17760592 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical peels
Number of subjects: 10
Study 17760592 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdermabrasion
Number of subjects: 10
Study 17760592 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue or blue/red light combinations
Number of subjects: 10
Study 17760592 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,450-nm diode laser
Number of subjects: 10
Study 17760592 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with 5-aminolevulinic acid or indocyanine green
Number of subjects: 10
Study 17760592 — intervention group
Group type: EXPERIMENTAL
Intervention: New procedural therapies (radiofrequency, light or laser, photodynamic therapy)
Number of subjects: 10
Study 15500555 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU daily of IFN alfa‐2b for 4 weeks followed by IFN (5 MU TIW) plus ribavirin (1000/1200 mg/daily) for 48 weeks (group 1)
Number of subjects: 151
Study 15500555 — intervention group
Group type: COMPARATOR
Intervention: 5 MU TIW of IFN alfa 2b for 4 weeks followed by IFN (5 MU TIW) plus ribavirin (1000/1200 mg/daily) for 48 weeks (group 2)
Number of subjects: 151
Study 15500555 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SVR in patients with genotype 2/3
Number of subjects: 151
Study 15500555 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SVR in patients with genotype 1/4
Number of subjects: 151
Study 15500555 — intervention group
Group type: EXPERIMENTAL
Intervention: SVR in genotype 1/4 patients younger than 40 years
Number of subjects: 151
Study 15500555 — intervention group
Group type: EXPERIMENTAL
Intervention: SVR in genotype 1/4 patients older than 40 years
Number of subjects: 151
Study 15500555 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of nonresponse to retreatment in younger genotype 1/4 patients compared to genotype 2/3 patients
Number of subjects: 151
Study 15500555 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of nonresponse to retreatment in older genotype 1/4 patients compared to genotype 2/3 patients
Number of subjects: 151
Study 11256836 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade with UFT (400 mg/day)
Number of subjects: 142
Study 11256836 — intervention group
Group type: COMPARATOR
Intervention: Combined androgen blockade without UFT
Number of subjects: 142
Study 10352494 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) therapy for 3 months
Number of subjects: 10
Study 10352494 — intervention group
Group type: COMPARATOR
Intervention: Baseline eosinophil percentage
Number of subjects: 10
Study 10352494 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in FEV1% between baseline and post-treatment
Number of subjects: 10
Study 10352494 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of log Dmin
Number of subjects: 10
Study 7655780 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 (3 x 10(6) IU/day subcutaneously for 4 weeks) plus melatonin (40 mg/day orally)
Number of subjects: 100
Study 7655780 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 100
Study 2403616 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 38
Study 2403616 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 38
Study 642947 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)‐Aerosol
Number of subjects: 25
Study 642947 — intervention group
Group type: COMPARATOR
Intervention: Placebo‐aerosol
Number of subjects: 25
Study 29624832 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Interpersonal Therapy (MIT-G)
Number of subjects: 20
Study 29624832 — intervention group
Group type: COMPARATOR
Intervention: Waiting list + Treatment as Usual (TAU)
Number of subjects: 20
Study 28467116 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined self-administered foot massage and CBT
Number of subjects: 53
Study 25599690 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strategy intervention including printed information, treatment-compliance check cards, and text messages.
Number of subjects: 358
Study 25599690 — intervention group
Group type: COMPARATOR
Intervention: Routine recommendations from physicians according to European clinical practice guidelines.
Number of subjects: 358
Study 22846234 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-checkout lanes
Number of subjects: 216
Study 20863941 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0‐mm resorbable screws
Number of subjects: 11
Study 20863941 — intervention group
Group type: COMPARATOR
Intervention: 1.5‐mm titanium screws
Number of subjects: 11
Study 18216051 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-flowing group (saline irrigation)
Number of subjects: 64
Study 18216051 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase group (streptokinase irrigation)
Number of subjects: 64
Study 18216051 — intervention group
Group type: COMPARATOR
Intervention: Saline group (saline irrigation)
Number of subjects: 64
Study 16153217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 or 20 mg
Number of subjects: 2102
Study 16153217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2102
Study 14690014 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (80 mg every other day for 6 weeks) + rifampicin (600 mg/day) + doxycycline (200 mg/day) for 6 weeks
Number of subjects: 71
Study 14690014 — intervention group
Group type: COMPARATOR
Intervention: Control group (rifampicin 600 mg/day + doxycycline 200 mg/day for 6 weeks)
Number of subjects: 71
Study 10378072 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (supervised 45-50 minute sessions, 85% of 1-RM, three days a week for 14 weeks)
Number of subjects: 24
Study 10378072 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 24
Study 10378072 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 24
Study 8616937 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol/Niacin plus diet
Number of subjects: 162
Study 8616937 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus diet
Number of subjects: 162
Study 2069382 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef (LY163892) at 200 mg once daily (n = 53)
Number of subjects: 108
Study 2069382 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor at 250 mg three times daily (n = 55)
Number of subjects: 108
Study 6368355 — intervention group
Group type: EXPERIMENTAL
Intervention: +cyanidanol-3 (3 gm per day for 8 weeks)
Number of subjects: 160
Study 6368355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 31314050 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin-Ezetimibe
Number of subjects: 2798
Study 31314050 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin-Placebo
Number of subjects: 2798
Study 29710825 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific amino acid composition with micronutrients
Number of subjects: 59
Study 29710825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 26931369 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and capecitabine combination chemotherapy with sequential telomerase GV1001 vaccine (n=18)
Number of subjects: 38
Study 26931369 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and capecitabine combination chemotherapy with concomitant telomerase GV1001 vaccine (n=24)
Number of subjects: 38
Study 26931369 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and capecitabine combination chemotherapy
Number of subjects: 38
Study 24405830 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboccipital muscle inhibition (SMI) technique for 4 minutes
Number of subjects: 40
Study 24405830 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) intervention
Number of subjects: 40
Study 22905596 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hypoallergenic 6-grass pollen preparation (SCIT)
Number of subjects: 0
Study 22905596 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 20235638 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT alone
Number of subjects: 180
Study 20235638 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT plus IFN-alpha
Number of subjects: 180
Study 20235638 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha alone
Number of subjects: 180
Study 17097812 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Graves' thyrotoxicosis
Number of subjects: 31
Study 17097812 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients after reaching euthyroidism
Number of subjects: 31
Study 17097812 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients 1 year after treatment initiation
Number of subjects: 31
Study 17097812 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 17140723 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephron-sparing surgery (NSS)
Number of subjects: 541
Study 17140723 — intervention group
Group type: COMPARATOR
Intervention: Radical nephrectomy (RN)
Number of subjects: 541
Study 15236831 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg daily)
Number of subjects: 41
Study 15236831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11009132 — intervention group
Group type: EXPERIMENTAL
Intervention: Maryland WIC 5-A-Day Promotion Program (intervention)
Number of subjects: 3122
Study 11009132 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3122
Study 9366459 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 microg x kg(‐1) x h(‐1) naloxone (low dose)
Number of subjects: 60
Study 9366459 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg x kg(‐1) x h(‐1) naloxone (high dose)
Number of subjects: 60
Study 9366459 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study 1286492 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 115
Study 1286492 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 115